Taft attorney Stephen Auten will present at the American Conference Institute's Paragraph IV Disputes Conference, part of its Hatch-Waxman series. The conference will take place Sept. 30-Oct. 1 at the InterContinental Chicago Magnificent Mile. Auten’s presentation is titled “Paragraph IV Due Diligence Analysis: Economic Impact of Pharmaceutical Patent Wins and Losses at District Courts and PTAB.”

Auten is head of Taft's Pharmaceutical and Life Sciences Litigation practice. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDA Litigation Forum," which has more than 6,000 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.